Peter A. Blomgren - North Branford CT, US Seung H. Lee - Branford CT, US Scott A. Mitchell - East Haven CT, US Jianjun Xu - Branford CT, US Aaron C. Schmitt - Hamden CT, US Jeffrey E. Kropf - Branford CT, US Kevin S. Currie - North Branford CT, US
At least one chemical entity chosen from compounds of Formula 1Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
Peter A. Blomgren - North Branford CT, US Kevin S. Currie - North Branford CT, US Seung H. Lee - Branford CT, US Scott A. Mitchell - East Haven CT, US Jianjun Xu - Branford CT, US Aaron C. Schmitt - Hamden CT, US Zhongdong Zhao - Guilford CT, US Pavel E. Zhichkin - Delmar NY, US Douglas G. Stafford - Niskayuna NY, US Jeffrey E. Kropf - Branford CT, US
Rajagopal Bakthavatchalam - Madison CT, US Scott M. Capitosti - Middletown CT, US Jianjun Xu - Branford CT, US Bertrand L. Chenard - Waterford CT, US Manuka Ghosh - Madison CT, US Charles A. Blum - Westbrook CT, US
Peter A. Blomgren - North Branford CT, US Kevin S. Currie - North Branford CT, US Jeffrey E. Kropf - Branford CT, US Tony Lee - Branford CT, US James W. Darrow - Wallingford CT, US Scott A. Mitchell - East Haven CT, US Jianjun Xu - Branford CT, US Aaron C. Schmitt - Hamden CT, US
Assignee:
Gilead Connecticut, Inc. - Foster City CA
International Classification:
C07D 409/00 A61K 31/44
US Classification:
5462811, 514333
Abstract:
At least one chemical entity chosen from compounds of Formula 1Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
Certain Substituted Amides, Method Of Making, And Method Of Use Thereof
Peter A. Blomgren - North Branford CT, US Kevin S. Currie - North Branford CT, US Seung H. Lee - Branford CT, US Scott A. Mitchell - East Haven CT, US Jianjun Xu - Branford CT, US Aaron C. Schmitt - Hamden CT, US Zhongdong Zhao - Guilford CT, US Pavel E. Zhichkin - Delmar NY, US Douglas G. Stafford - Niskayuna NY, US Jeffrey E. Kropf - Branford CT, US
Assignee:
Gilead Connecticut, Inc. - Foster City CA
International Classification:
C07D 241/36 A61K 31/4965
US Classification:
544338, 51425505
Abstract:
Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
Certain Substituted Amides, Method Of Making, And Method Of Use Thereof
Peter A. Blomgren - North Branford CT, US David R. Brittelli - Branford CT, US Kevin S. Currie - North Branford CT, US Seung H. Lee - Branford CT, US Jeffrey E. Kropf - Branford CT, US Scott A. Mitchell - East Haven CT, US Aaron C. Schmitt - Hamden CT, US Xiaojing Wang - Foster City CA, US Jianjun Xu - Madison CT, US Zhongdong Zhao - Guilford CT, US Pavel E. Zhichkin - Delmar NY, US
Assignee:
CGI Pharmaceuticals, Inc. - Branford CT Genentech, Inc. - South San Francisco CA
Scott A. Mitchell - East Haven CT, US Kevin S. Currie - North Branford CT, US Peter A. Blomgren - North Branford CT, US Jeffrey E. Kropf - Branford CT, US Seung H. Lee - Branford CT, US Jianjun Xu - Branford CT, US Douglas G. Stafford - Niskayuna NY, US
Scott A. Mitchell - East Haven CT, US Kevin S. Currie - North Branford CT, US Peter A. Blomgren - North Branford CT, US Jeffrey E. Kropf - Branford CT, US Seung H. Lee - Branford CT, US Jianjun Xu - Madison CT, US Douglas G. Stafford - Niskayuna NY, US James P. Harding - Loudonville NY, US Antonio J. M. Barbosa, Jr. - Bonita Springs FL, US Zhongdong Zhao - Guilford CT, US Soumya Mitra - Liverpool NY, US David M. Armistead - Sudbury MA, US
Assignee:
Gilead Connecticut, Inc. - Foster City CA
International Classification:
A61K 31/495
US Classification:
514249, 544117, 546113, 5483611, 548516
Abstract:
Certain imidazopyrazines of Formula (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.